Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Abraham C. F. Leung"'
Autor:
Paula M. Fracasso, Christine Gennigens, Carol Zhao, Vincent Armenio, Linda Duska, Ignace Vergote, John Micha, Gordon J. S. Rustin, Abraham C. F. Leung, C. H. Pippitt, Agustin A. Garcia, Johanna C. Bendell, Nicholas S. Reed, Daniel Lewis Spitz, Raoudha Soufi-Mahjoubi, Graham Dark, Christopher J. Poole, Luc Y. Dirix, Emad Ibrahim
Publikováno v:
Journal of Clinical Oncology. 31:4060-4066
Purpose Etirinotecan pegol (NKTR-102) is a unique, long-acting topoisomerase-I inhibitor with prolonged systemic exposure to SN38 (7-ethyl-10-hydroxycamptothecin), the active metabolite of irinotecan. This randomized phase II trial investigated two d
Autor:
Abraham C. F. Leung, Douglas Earl Laux, Deborah Wong, Lisle Nabell, Biao Xing, Asim Amin, Robert Janssen, Sarwan Bishnoi, Ezra E.W. Cohen, Emmett V. Schmidt
Publikováno v:
Cancer Research. 78:CT098-CT098
Background and Objectives: SD-101 is a synthetic CpG-ODN agonist of TLR9 that stimulates dendritic cells to release IFN-alpha and mature into antigen presenting cells to activate T cell anti-tumor responses. Pembrolizumab is a PD-1 inhibitor that has
Autor:
Joseph J. Drabick, Gregory A. Daniels, Robert Janssen, Antoni Ribas, Minal A. Barve, Shivaani Kummar, Theresa Medina, Abraham C. F. Leung, Emmett V. Schmidt, Asim Amin, Deborah L. Wong
Publikováno v:
Cancer Research. 78:CT139-CT139
Background: This phase 1b trial evaluates the safety and antitumor efficacy of the combination of SD-101, a synthetic CpG-oligonucleotide that stimulates Toll-like receptor 9 (TLR9), and pembrolizumab in patients with recurrent Stage IIIC/IV malignan
Autor:
Robert L. Coffman, Albert Candia, Graeme Currie, Rene Gonzalez, Robert Janssen, Cristiana Guiducci, Joseph J. Drabick, John Nemunaitis, Abraham C. F. Leung, Antoni Ribas, Shivaani Kummar, Sanjiv S. Agarwala
Publikováno v:
Cancer Research. 77:LB-239
Introduction: SD-101 is a synthetic CpG oligonucleotide agonist of Toll-like receptor 9. SD-101 stimulates dendritic cells to release interferon-alpha and mature into antigen presenting cells that effectively activate T cell responses. Pembrolizumab
Autor:
Sanjiv S. Agarwala, Emmett V. Schmidt, Biao Xing, Graeme Currie, Abraham C. F. Leung, Robert Janssen, Elliot Chartash, Rene Gonzalez, Antoni Ribas, Shivaani Kummar, John Nemunaitis, Joseph J. Drabick
Publikováno v:
Journal of Clinical Oncology. 35:9550-9550
9550 Background: SD-101 is a synthetic CpG-ODN agonist of TLR 9 that stimulates dendritic cells to release IFN-alpha and mature into antigen presenting cells to activate T cell anti-tumor responses. Pembro is a PD-1 inhibitor approved for the treatme
Autor:
Hans Wildiers, Antonio González-Martín, Abraham C. F. Leung, Jean-Marc Ferrero, Ian E. Krop, Sung-Bae Kim, Patricia LoRusso, Ron Yu, Melanie Smitt
Publikováno v:
The Lancet. Oncology. 15(7)
Patients with progressive disease after two or more HER2-directed regimens for recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to compare trastuzumab emtansine, an antibody-drug conjugate comprising the cytotoxi
Autor:
Olivier Chinot, Mohamed Bekradda, Keyvan Rezai, Jean-Pierre Delord, Marc Sanson, Abraham C. F. Leung, Nicolas Lachaux, Andreas F. Hottinger, Rita De Micheli, François Lokiec, Elizabeth Cohen-Jonathan Moyal, Susan Perez
Publikováno v:
Journal of Clinical Oncology. 34:e14123-e14123
e14123Background: Bromodomains (BRD) bind to acetylated lysine residues on histone tails and are directly involved in remodeling chromatin and regulating transcription, thus representing a potentially important anticancer target. MK-8628 is a synthet
Autor:
Caroline Trudeau, Hans Wildiers, Jennifer Kang, Karen Bartley, Ron Yu, Abraham C. F. Leung, Antonio González-Martín, Ian E. Krop, Sung-Bae Kim
Publikováno v:
Journal of Clinical Oncology. 32:153-153
153 Background: Progression-free survival and objective response rate were significantly improved with T-DM1 vs TPC in TH3RESA. The impact of treatment on quality of life is a key aspect in determining treatment value. Here we present the PRO results
Autor:
Caroline Trudeau, Ian E. Krop, Ron Yu, Sanne de Haas, Abraham C. F. Leung, Hans Wildiers, Sung-Bae Kim, Antonio González-Martín
Publikováno v:
Journal of Clinical Oncology. 32:605-605
605 Background: T-DM1, an antibody–drug conjugate comprising trastuzumab, DM1 (microtubule inhibitor), and a stable linker, is approved for patients (pts) with HER2-positive metastatic BC previousl...
Publikováno v:
Journal of Clinical Oncology. 30:5048-5048
5048 Background: NKTR-102 is a unique topoisomerase 1 inhibitor that provides continuous exposure to SN38. In heavily pretreated pts with PROC (median of 3 prior therapies; 27 pts were platinum refractory), 145 mg/m2 NKTR-102 given q14d or q21d demon